PPM1N (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:147699, HGNC:26845, NM_001080401, NM_178494, NP_001073870, PPM1N, XR_001753603, XR_002958254, protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)

Id:ENSG00000213889

Hgnc:HGNC:26845

Entrez:147699

Ensembl:ENSG00000213889

Description:protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)

Predicted to enable metal ion binding activity and protein serine/threonine phosphatase activity. Predicted to be involved in negative regulation of I-kappaB kinase/NF-kappaB signaling and positive regulation of canonical Wnt signaling pathway. Predicted to be active in cytosol and nucleus. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View PPM1N's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with PPM1N.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using PPM1N.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for PPM1N.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with PPM1N.

Results found

Linked to

	Label	Description
	GSE145990 1 V 0 IBRUTINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 0 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680,GSE182683 10 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE172458 0 V 1 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE161073 IDH1 inhibition 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

GSE145990 1 V 0 IBRUTINIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 0 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 3 v 7 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE182680,GSE182683 10 V 4 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE172458 0 V 1 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE161073 IDH1 inhibition 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.